Advertisement
Research Article Free access | 10.1172/JCI106868
1Department of Medicine, Washington University School of Medicine, and The Jewish Hospital of St. Louis, Missouri 63110
Find articles by Hahn, T. in: PubMed | Google Scholar
1Department of Medicine, Washington University School of Medicine, and The Jewish Hospital of St. Louis, Missouri 63110
Find articles by Birge, S. in: PubMed | Google Scholar
1Department of Medicine, Washington University School of Medicine, and The Jewish Hospital of St. Louis, Missouri 63110
Find articles by Scharp, C. in: PubMed | Google Scholar
1Department of Medicine, Washington University School of Medicine, and The Jewish Hospital of St. Louis, Missouri 63110
Find articles by Avioli, L. in: PubMed | Google Scholar
Published April 1, 1972 - More info
The metabolic fate of intravenously injected vitamin D3-1,2-3H (D3-3H) was studied in two normal individuals on chronic phenobarbital therapy. Silicic acid column chromatography of lipid-soluble plasma extracts obtained serially for 96 hr after D3-3H injection demonstrated a decreased plasma D3-3H half-life and increased conversion to more polar metabolites. The polar metabolites formed included several with chromatographic mobility similar to known biologically inactive vitamin D metabolites and one with chromatographic mobility identical to 25-hydroxycholecalciferol. Disappearance of this latter material was also accelerated. A child with rickets and a normal volunteer studied before and after a 2 wk course of phenobarbital therapy demonstrated similar alterations in D3-3H metabolism. When liver microsomes from 3-wk-old Sprague-Dawley rats treated with phenobarbital were incubated with D3-3H, polar metabolites were produced with chromatographic mobility similar to the plasma D3-3H metabolites from phenobarbital-treated humans. Similar incubations employing 25-hydroxy-cholecalciferol-26-27-3H as the substrate also demonstrated an increased conversion to polar metabolites. The data suggest that the reported increased incidence of osteomalacia observed in patients on chronic anticonvulsant therapy may be the result of an accelerated conversion of vitamin D and its active metabolite, 25-hydroxycholecalciferol, to polar metabolites by druginduced liver microsomal enzymes.